SCHEMBL517020

SCHEMBL517020

O=C(O)c1sccc1C(=O)N(F)c1c(F)cc(-c2cccc(OC(F)(F)F)c2)c(F)c1F

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 16/20 0.58
CTSA P10619 2/20 0.41
LDHA P00338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17242642 0.88 DHODH (0.61) DHODHCTSALDHA
SCHEMBL299934 0.82 DHODH (0.55) DHODH
SCHEMBL517490 0.81 DHODH (0.55) DHODH
SCHEMBL517795 0.78 DHODH (0.43) DHODH
SCHEMBL4399442 0.78 DHODH (0.43) DHODH
SCHEMBL1124231 0.74 DHODH (0.55) DHODHCTSA
SCHEMBL517805 0.73 DHODH (1.00) DHODH
Kio-100 SCHEMBL517019 0.73 DHODH (1.00) DHODH
SCHEMBL517841 0.71 DHODH (0.44) DHODH
SCHEMBL517921 0.71 DHODH (0.53) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209073-B2 Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor KIORA PHARMACEUTICALS GMBH (AT) 2025-01-28 US claimed
EP-3761960-B1 OPHTHALMIC FORMULATION KIORA PHARMACEUTICALS GMBH (DE) 2023-11-22 EP claimed
WO-2023172818-A1 POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR KIORA PHARMACEUTICALS GMBH (AT) 2023-09-14 WO claimed
US-20230286938-A1 POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR PANOPTES PHARMA GMBH (AT) 2023-09-14 US claimed
US-11730716-B2 Compounds for treating ophthalmic diseases and disorders KIORA PHARMACEUTICALS GMBH (AT) 2023-08-22 US claimed
CN-111163757-B Ophthalmic preparation 帕诺泰斯制药有限公司 2022-04-19 CN claimed
EP-2427186-B1 DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS PANOPTES PHARMA GES M B H (AT) 2022-01-12 EP claimed
US-20210052737-A1 OPHTHALMIC FORMULATION PANOPTES PHARMA GES.M.B.H (AT) 2021-02-25 US claimed
EP-3761960-A1 OPHTHALMIC FORMULATION Panoptes Pharma GmbH (AT) 2021-01-13 EP claimed
CN-111163757-A Ophthalmic preparation 帕诺泰斯制药有限公司 2020-05-15 CN claimed
WO-2019170848-A1 OPHTHALMIC FORMULATION PANOPTES PHARMA GES.M.B.H. (AT) 2019-09-12 WO claimed
US-9795590-B2 Anti-inflammatory agents as virostatic compounds PANOPTES PHARMA GMBH (AT) 2017-10-24 US claimed
US-20170027905-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS Panoptes Hparma GmbH (AT) 2017-02-02 US claimed
US-8354433-B2 Anti-inflammatory agents as virostatic compounds 4SC AG (DE) 2013-01-15 US claimed
US-20250381167-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS KIORA PHARMACEUTICALS GMBH (AT) 2025-12-18 US disclosed
US-12472263-B2 Ophthalmic formulation PANOPTES PHARMA GES.M.B.H (AT) 2025-11-18 US disclosed
US-12364680-B2 Compounds for treating ophthalmic diseases and disorders KIORA PHARMACEUTICALS GMBH (AT) 2025-07-22 US disclosed
EP-1578741-A1 AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2005-09-28 EP disclosed
US-20040192758-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2004-09-30 US disclosed
WO-2004056797-A1 AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209073-B2 Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor DHODH, DPYD, DLD DHODH 1/4885CTSA 1430/4885LDHA 215/4885
US-20230286938-A1 POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR DHODH, DPYD, DLD DHODH 1/4885CTSA 1430/4885LDHA 215/4885
US-11730716-B2 Compounds for treating ophthalmic diseases and disorders DHODH, ALDH1A2, QDPR DHODH 1/4885CTSA 2667/4885LDHA 970/4885
US-20250381167-A1 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS DHODH, ALDH1A2, QDPR DHODH 1/4885CTSA 2667/4885LDHA 970/4885
US-20170027905-A1 ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS TNF, RPL35, NFKBIA DHODH 2832/4885CTSA 82/4885LDHA 274/4885
US-12364680-B2 Compounds for treating ophthalmic diseases and disorders DHODH, ALDH1A2, QDPR DHODH 1/4885CTSA 2667/4885LDHA 970/4885
US-20040192758-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents PPARG, PPARD, PPARA DHODH 3023/4885CTSA 184/4885LDHA 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.